Despite regulatory initiatives, 40% of drugs for children and 90% for neonates are prescribed off-label due to challenges like enrollment difficulties, dose selection uncertainties, and ethical complexities. Simcyp Pediatric overcomes these hurdles with its advanced PBPK modeling capabilities.
Simcyp™ Pediatric
Advanced PBPK modeling for pediatric drug development
Learn more about Simcyp Pediatric
Comprehensive pediatric pharmacokinetics modeling
Simcyp Pediatric is a module within the Simcyp PBPK Simulator, designed to model pharmacokinetic behavior in neonates, infants, and children. By leveraging physiologically-based pharmacokinetic (PBPK) modeling, it provides critical insights into dosing decisions, drug-drug interactions, and the design of pediatric clinical studies.
The Simcyp PBPK Simulator integrates extensive libraries on demographics, developmental physiology, and drug elimination pathways, linking in vitro data to in vivo ADME and pharmacokinetic/pharmacodynamic (PK/PD) outcomes. This innovative tool supports informed decision-making and minimizes the exposure of children to experimental therapies.
Advancing pediatric drug development using Simcyp PBPK
View our collection of case studies for neonate/child dosing, drugs for children’s diseases, DDIs for pediatrics, and developing child-specific formulations.
Benefits of Simcyp Pediatric
Related solutions
Related resources
View allSchedule a demo
Experience Simcyp Pediatric in Action
Schedule a demo to see how Simcyp Pediatric can transform your pediatric drug development process.
Contact us
Simcyp Pediatric FAQs
What is Simcyp Pediatric?
Simcyp Pediatric is a module within the Simcyp Simulator that models pharmacokinetic behavior in neonates, infants, and children using PBPK modeling.
How does Simcyp Pediatric support pediatric drug development?
It provides insights into dosing, drug-drug interactions, and clinical trial design, minimizing the need for experimental exposure in children.
Can Simcyp Pediatric predict pharmacokinetics for all pediatric age ranges?
Yes, it can predict pharmacokinetics for neonates, infants, children, and adolescents using in vitro or adult in vivo data.